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I
n a world of lightning fast information, where competition for resources now occurs 
on a global scale, where innovation is progressing faster than any other time in 
human history: is the slow, considered application of ethical principles still relevant? 
Or do ethics burden the already self-regulating principles of the free-market with 
impractical philosophy?
Welcome to a truly bumper issue of AQ. In this year’s Special Edition we look at what role 
ethics still has to play in our lives, from climate change, to medicine, through to the depths 
of the internet.
How does the concept of ethics play into our everyday, where is it critical that ethical 
standard remain enforced and where have we let our ethical responsibilities be usurped by 
politicking and fear?
We are very lucky to have Julian Burnside QC returning to the pages of AQ, providing 
a long, hard look at the last 15 years of Australia’s border policy. The piece is a powerful 
reminder of how far we have strayed from the Aussie values of the fair go that we, perhaps 
wrongly, still wear as a badge of national pride.
In recent years the Àeld of genome editing has been thrown open by the development of simpler, 
cheaper and more accurate methods of altering the DNA of any living organism. Prominent 
bioethicists, Dr Ainsley Newson and Dr Anthony Wrigley walk us through the issues in an 
area of science that could fundamentally change the idea of what it is to be human.
Australia’s two biggest political footballs continue to be ‘refugees’ and ‘climate change’. But 
what happens when the two become one, and we begin seeing climate-refugees, those that 
have been pushed off their land by rising sea levels and extreme weather patterns? How will 
Australia react, and should our ethical responsibilities to these people begin before they even 
leave their home country?
We also examine whether ethics can or should be applied to IT and the internet, investigate 
the balancing act between ethics and innovation, and take a look at the history of Australia’s 
political party Think Tanks. 
It’s an exciting issue that I hope will entertain as well as challenge. Share your thoughts via 
our Facebook (@AQAustralianQuarterly) or Twitter (@AQjournal).
Grant Mills
Editor
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Genetic engineering in itself is, of course, not new – various techniques that allow scien-tists to modify genes have been around for some time. 
But the difference with genome editing 
is that it is simple, cheap, and accurate; 
thereby opening up the potentials of 
genetic engineering on a hitherto unseen 
scale. 
Genome editing has a broad range of 
possible applications in areas such as novel 
medical treatments, vaccine development, 
Genome editing can be viewed as a disruptive technology 
– fundamentally changing how scientists alter genomes. 
Despite the technique remaining imperfect, there is now a 
real possibility that we can precisely and accurately change 
almost any part of any genome, including plants, animals, 
and human beings. The question is, should we?
ARTICLE BY: DR AINSLEY NEWSON & DR ANTHONY WRIGLEY
Being Human: 
The Ethics, Law, and Scientific 
Progress of Genome Editing
This paper draws on a Background Paper on 
Genome Editing, which the authors prepared 
for the Nuffield Council on Bioethics (UK).  
The report can be accessed online.1
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BEING HUMAN
crop innovation and environmental reme-
diation. A variety of approaches fit the 
genome editing moniker, but the emer-
gence of CRISPR-Cas9 has captured the 
most attention. 
What is CRISPR-Cas9?
Editing a genome involves introduc-
ing a change to a chosen target within a 
cell’s DNA. The change can take numerous 
forms, from introducing a small deletion to 
effecting a precise sequence change.
There are several methods of genome 
editing, but CRISPR-Cas9 is currently the 
easiest to set up and use. The CRISPR-Cas9 
technique was first published in 2012,2 
but is based on a knowledge of short 
DNA sequences found in simple cells; 
around since the 1980s. “CRISPR” stands 
for “clustered regularly interspaced short 
palindromic repeats”. 
The technique involves two main steps. 
First, components of a custom-designed 
nuclease (called an endonuclease) are 
introduced to a recipient cell, whereupon 
they self-assemble. This endonuclease 
then targets and cuts one or both strands 
of a chosen DNA sequence. Second, the 
recipient cell’s inherent DNA-repair machin-
ery then repairs the cut and in so doing, 
introduces the designed change. These 
changes can comprise anything from a 
single base pair change to the insertion or 
deletion of whole genes.3,4
CRISPR-Cas9 is a very flexible system 
and can be used without expert protein 
engineering expertise. The nature of the 
method also means that several changes 
can be introduced to a cell simultaneously. 
Scientific publications using this system are 
rapidly increasing; with over 800 citations 
in the database PubMed as at November 
2015.
However, despite its simplicity and rela-
tively low cost, CRISPR-Cas9 is not perfect. 
Problems can arise, such as ‘off target’ cleav-
age, which occurs when the endonuclease 
attaches to and cuts at the wrong site in 
the DNA helix. There are also concerns that 
unwanted DNA repair events will occur. 
One paper in 
particular among 
the increasing 
literature has 
led to significant 
debate. In April 
2015, a Chinese 
research team 
published the first 
(albeit not very 
successful) use of CRISPR-Cas9 in human 
embryos; with the aim of engineering out 
the mutation that causes β-thalassemia.5 
If these embryos were implanted (which 
was not the intention of this work) they 
could have led to the birth of humans with 
an engineered germ-line – meaning that 
the changes could be passed to future 
generations. The experiment was subject 
to criticism on both scientific and ethical 
grounds and soon after, the National 
Institutes of Health in the United States 
announced that it would not fund research 
that used genome editing in human 
embryos.6
Caplan et al rightly point out, however, 
that our examination of ethical aspects 
of CRISPR-Cas9 should not become too 
narrow in focus.7 While genome editing 
in embryos is ethically significant, issues 
also arise in other applications: generating 
transgenic animals; developing novel ther-
apies in humans and releasing genetically 
modified organisms (GMOs). CRISPR-Cas9 
may represent a ‘tipping point’ for ethics; a 
point we return to below.
What Role for Bioethics?
The power and precision of this tech-
nology means that it’s no surprise that 
everyone involved recognises how its 
implications could be profound. The issue is 
getting the balance right between respon-
sible deliberation and governance; and 
facilitating the development of promising 
interventions. 
Bioethics has historically been a dis-
cipline in which philosophers have 
developed arguments on key concepts 
or developments in science, health and 
medicine. Other disciplines, such as law 
and sociology have also entered the fray, 
resulting in an ongoing debate over the 
scope and methods of bioethics and the 
nature of expertise within the field. Sitting 
In April 2015, a Chinese research team 
published the first (albeit not very successful) 
use of CRISPR-Cas9 in human embryos;  
with the aim of engineering out the mutation 
that causes β-thalassemia.
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The central underlying ethical concern here is one that applies 
to any application of human genetic modification: that it may 
unintentionally change the genome forever.
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alongside academic bioethics is research 
ethics; or the manner of approving research 
studies that involve human or certain 
non-human animal participants; or which 
involve ethically contested materials such 
as human embryos. 
Writing about CRISPR in August 2015, 
psychologist Stephen Pinker presented his 
view on the role of ethics in the genome 
editing debate, stating that bioethicists 
should “get out of the way”.8 He was con-
cerned that bioethicists holds up scientific 
progress (causing harm) and broker moral 
panic. He criticised bioethicists for mis-pre-
dicting the future and over-inflating risks. 
He implied that ample existing protec-
tions and informed consent processes are 
enough to allow genome editing to safely 
prosper. 
Our take on Pinker’s piece and the 
ensuing debate (of which there was plenty) 
is that we need to be careful not to tar aca-
demic bioethics with the same brush that is 
used for the definitely imperfect and often 
cumbersome research ethics process. 
Pinker also pitches an unfair stereotype 
of bioethics; not one that we recognise 
as representing the discipline. Bioethics 
is inherent to the development of new 
technologies. Its role is not one of simply 
pointing out all the problems with a tech-
nology or stating why something shouldn’t 
be done. The challenge for bioethics is 
to work in collaboration with researchers 
to scope issues, frame the potential of 
genome editing as accurately as possible, 
and to find ways to appropriately facilitate 
promising research.
Should We Be Worried About 
CRISPR-Cas9?
The ethics of genetic modification, 
particularly involving humans, has had 
an uncomfortable history which has 
often given rise to a highly precautionary 
approach to its use. In other words: don’t 
do anything until you know for sure that 
it will be safe and beneficial. And while 
genome editing may not present us with 
any specifically new ethical issues con-
cerning genetic modification – it is in that 
regard just another technique that allows 
such modifications to take place – that is 
not the end of the story. 
The important question is not, there-
fore, whether genome editing raises new 
questions. Instead, we need to ask whether 
genome editing warrants further special 
attention than has already been given to 
the ethics of genetic engineering in its 
various forms.
The major concern driving the call for 
this further attention is a direct result of 
genome editing’s potential for success. As 
it is so effective and easy to use, there are 
worries that it may be put into use far too 
rapidly. This, in turn, will have implications 
for the ethical debate as the use of the 
technique may outstrip our understanding 
of its safety and our window of opportu-
nity to think about whether - and how - it 
should be controlled.
So just what are the ethical aspects 
surrounding genome editing? As indicted 
above, modifying the human genome 
gives rise to the most concern. The central 
underlying ethical concern here is one 
that applies to any application of human 
genetic modification: that it may unin-
tentionally change the genome forever; 
Even within the boundaries of legitimate 
scientiÀc enterprise, there are concerns about 
‘directed evolution’.
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Regulation and Oversight
In Australia, genome editing will be 
subject to regulation under several 
existing instruments. For example, the 
genome editing of crops will fall under 
the ambit of the Gene Technology Act 
2000 (Cth) and the relevant procedures 
it dictates, including licensing. In 
humans, somatic (non-inheritable) 
gene therapy is likely to require 
approval from a Human Research Ethics 
Committee. 
If a clinical trial, the Therapeutic 
Goods Act 1989 (Cth) and clinical trial 
regulations will also apply; as may 
the Gene Technology Act; although the 
definition of a ‘genetically modified 
organism’ (GMO) under the Gene 
Technology Act specifically excludes a 
human who is only modified due to 
having undergone somatic cell gene 
therapy (s10). 
The permissibility of genome editing 
research in human embryos will be 
dictated by the Research on Human 
Embryos Act 2002, as amended (Cth) 
and the Prohibition of Cloning for 
Reproduction Act 2002, as amended 
(Cth) (as well as mirroring legislation 
in states and territories). These laws 
permit certain types of embryo 
research, subject to licence. However 
until a licence is applied for we cannot 
predict how the legislation will be 
interpreted; especially because genome 
editing did not exist at the time these 
laws were written. 
A search of the NHMRC licensing 
database indicates that at the time of 
writing, no licences involving the use 
of genome editing in human embryos 
in Australia have been granted nor 
applied for. 
causing harm.  This is a debate that has 
long been considered and which often 
underpins the difference between somatic 
and germ-line genetic modifications. 
Somatic-cell modifications allow for the 
therapeutic use of gene modification to 
help treat identifiable genetic disorders in a 
particular person. The crucial element is that 
these are non-heritable changes. Germ-line 
interventions, however, make changes that 
are heritable. While this has the advantage 
that unwanted genetic conditions may be 
permanently removed if the germ-line is 
altered safely and as intended, any errors or 
unwanted consequences from altering the 
germ-line will also be passed on. 
Genome editing is interesting in this 
regard because the accuracy of the tech-
nique minimises (although by no means 
eliminates) the risk of error and allows a 
much more nuanced genetic modifications 
to be made. However, even if changes to 
the genome turn out to be ‘safe’ there are 
implications arising from the scope and 
scale of the techniques. 
If a technique can be used widely and 
efficiently, without careful guidance of its 
use, a certain ‘tipping point’ can be reached 
that changes the status of the technology. 
Widespread use can change expectations 
to the point where genome editing would 
become a norm in many areas of life. 
Moreover, such massive increases in scope 
and scale may mean that current scientific 
governance may no longer be sufficient to 
deal with the wider implications surround-
ing such issues as access, resources and 
social impact of its use. 
The crossover between ethics and 
adequate governance in science seems 
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particularly acute in the case of genome 
editing. The creation of such a cheap 
and effective means of modifying genes 
can lead to a need to limit the potential 
for these techniques to be misapplied in 
other areas; what is known as the ‘dual use’ 
problem. These might include the genetic 
manipulation of viruses, gene transfer as 
a weapon, or commercial exploitation in 
crops and animals to produce specific traits. 
Even within the boundaries of legitimate 
scientific enterprise, there are concerns 
about ‘directed evolution’, whereby the 
boundaries of the scope of genome editing 
need to be established and decisions 
made about who should select the genetic 
properties of any organism to edit. This will 
require global agreements as to exactly 
how gene editing is to be managed. 
Although genome editing techniques 
present a relatively low cost means of 
achieving genetic modification, wider 
issues of social justice remain that attach to 
the equity in distributing its benefits. First 
amongst these would be whether equitable 
access to technology is both warranted and 
available. This may be a particular problem 
for low and middle income countries due 
to the likelihood that research interests will 
focus significantly on problems linked to 
‘Western’ medicine and disease. 
Commercialisation may further extend 
many potential inequalities if patents 
or other means of restricting access to 
resources developed through genome 
editing techniques take hold (and patents 
over CRISPR-Cas9 are already being granted 
and fought over). Imagine the situa-
tion where genome editing leads to the 
development of highly drought-resistant, 
disease-resistant, high-yield crops, destroy-
ing commercial opportunities for those 
who are unable to pay the high price 
demanded for the genetically altered 
product. Competitive advantage may be 
even further affected due to the disrup-
tive nature of genome editing, as it may 
supplant alternative gene-modification 
technologies. 
Social justice concerns have also been 
raised by specific interest groups that see 
genome editing as potentially directly 
affecting them. Should genome editing 
involving germ-line modifications go 
ahead, it has the potential to perma-
nently eradicate certain genetic disorders. 
Although this may seem at first glance like 
a universally good thing, some argue that 
the attempt to eradicate certain conditions 
permanently implies a lack of respect for 
people who have those genetic diseases 
by viewing not only the conditions them-
selves as something undesirable but also 
the existence in society of such people 
with those conditions. 
Concerns about social justice need not 
all be negative, however. Although only a 
small number of people are likely to benefit 
initially, the economic advantages of 
genome editing may readily lead to a rapid 
expansion of application of the technique. 
This, in turn, has the potential to benefit 
populations that are often disadvantaged 
under current conditions of scientific 
research and innovation, such as those who 
live with rare diseases that would otherwise 
not be viable areas of research. 
The development of research and 
testing of genome editing techniques on 
human populations in the first instance 
will, however, still be a major challenge. 
The nature of such trials, on whom, and 
how risks are assessed for research subjects 
and society in general will all have to be 
addressed. 
Is Genome Editing Legal?
There is currently little specific gov-
ernance of genome editing technology 
anywhere and it is an open question as 
to whether specific regulation is required. 
But at a minimum, it does seem appropri-
ate to query how genome editing will be 
governed in Australia (see Regulation and 
Oversight breakout, p 6) 
One broad consideration is to query 
what role governance could or should play 
in the development of any new technol-
ogy. What aspects of genome editing 
should be regulated, and how? While it 
is perhaps too early to answer this ques-
tion, considerations of the approach to 
governance and the need for regulation of 
Although only a small number of people are likely to benefit 
initially, the economic advantages of genome editing may 
readily lead to a rapid expansion of application of the technique. 
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When the recombinant DNA revolution occurred in 
the early 1970’s, scientists mutually agreed to a 
moratorium until more was known. 
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genome editing should not be forgotten as 
the field continues to develop. 
In recent years, academics and 
policy-makers who research emerging 
biotechnologies have been engaging in 
a dialogue over how to govern rapidly 
emerging biotechnologies. The problem 
is that legislation can be problematic: it is 
slow to make and difficult to change. Using 
regulations instead of statute laws is one 
way around this; as the recent regulations 
governing mitochondrial donation in the 
United Kingdom (UK) have shown.
In the UK and Europe, responsible 
research and innovation (RRI) has recently 
gained traction.  While there is not yet a 
single definition or approach to RRI, there 
are three common features: (i) democratic 
governance over the appropriate rationale 
and end-points for research and innovation; 
(ii) broadly framed responsiveness to current 
and future innovations and their impacts to 
both science and society; and (iii) framing 
‘responsibility’ within a climate of all stake-
holders working under uncertainty.9 RRI 
is also hallmarked by ongoing interaction 
between researchers and regulators. Yet RRI 
is also complex, requiring a significant com-
mitment of time and resources to ‘get right’. 
RRI does not yet seem to have entered the 
policy landscape in Australia; and it would 
be interesting to consider how such an 
approach might work here.
Do We Need A Moratorium?
One way to prevent problems arising 
from a new technology is not to do it at 
all. When the recombinant DNA revolution 
occurred in the early 1970’s, scientists 
mutually agreed to a moratorium until 
more was known. Something similar might 
be considered for genome editing; in par-
ticular its applications that could alter the 
human germ-line. In 2015, concerns about 
the implications of genome editing in 
humans and their descendants led to calls 
for a moratorium on the use of this tech-
nology where it might impact the human 
germ-line.10,11  Others have taken a position 
that encourages prudence and transpar-
ency, but stop short of a moratorium.12  
In our view, while moratoriums have 
been successfully used in the past, it’s 
not clear that one is indicated here. Most 
countries already have laws or guidelines in 
place that robustly regulate modifications 
of the human germ line. Further, a mora-
torium will prevent the exact research that 
we need to undertake to look carefully at 
is implications, such as safety and efficacy; 
which in turn will assist with weighing up 
the potential benefits, risks and harms. Thus 
instead of a blanket ban, we should instead 
encourage all nations to enforce restric-
tions on some applications of genome 
editing, until the ethics can be worked 
out. This should then be done with wide 
consultation and debate.
Where To Next?
Many of the ethical issues in genome 
editing also arise elsewhere. It does, 
however, create something of a new 
context arising from the implications of 
the scope of the techniques. Potentially 
infinitely editable genomes using an accu-
rate and relatively inexpensive technique 
presents the potential for changing many 
more aspects of the genome in humans, 
animals, plants and other organisms, and 
on a significantly greater scale, than has 
previously been considered. 
CRISPR-Cas9 is an exciting technology, 
with possible applications across almost 
all living species. The ethical issues arising 
from this should be considered openly by 
a variety of stakeholders. Genome editing 
also offers new opportunities to assess how 
we regulate and govern emerging technol-
ogies; including limitations to current legal 
approaches and opportunities to assess 
novel governance frameworks. AQ
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